FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3099532404> ?p ?o ?g. }

• W3099532404 endingPage "340" @default.
• W3099532404 startingPage "327" @default.
• W3099532404 abstract "In the absence of controlled trials, treatment of neonatal seizures has changed minimally despite poor drug efficacy. We tested bumetanide added to phenobarbital to treat neonatal seizures in the first trial to include a standard-therapy control group.A randomized, double-blind, dose-escalation design was employed. Neonates with postmenstrual age 33 to 44 weeks at risk of or with seizures were eligible. Subjects with electroencephalography (EEG)-confirmed seizures after ≥20 and <40mg/kg phenobarbital were randomized to receive additional phenobarbital with either placebo (control) or 0.1, 0.2, or 0.3mg/kg bumetanide (treatment). Continuous EEG monitoring data from ≥2 hours before to ≥48 hours after study drug administration (SDA) were analyzed for seizures.Subjects were randomized to treatment (n = 27) and control (n = 16) groups. Pharmacokinetics were highly variable among subjects and altered by hypothermia. The only statistically significant adverse event was diuresis in treated subjects (48% vs 13%, p = 0.02). One treated (4%) and 3 control subjects died (19%, p = 0.14). Among survivors, 2 of 26 treated subjects (8%) and 0 of 13 control subjects had hearing impairment, as did 1 nonrandomized subject. Total seizure burden varied widely, with much higher seizure burden in treatment versus control groups (median = 3.1 vs 1.2 min/h, p = 0.006). There was significantly greater reduction in seizure burden 0 to 4 hours and 2 to 4 hours post-SDA (both p < 0.01) compared with 2-hour baseline in treatment versus control groups with adjustment for seizure burden.Although definitive proof of efficacy awaits an appropriately powered phase 3 trial, this randomized, controlled, multicenter trial demonstrated an additional reduction in seizure burden attributable to bumetanide over phenobarbital without increased serious adverse effects. Future trials of bumetanide and other drugs should include a control group and balance seizure severity. ANN NEUROL 2021;89:327-340." @default.
• W3099532404 created "2020-11-23" @default.
• W3099532404 creator A5014884565 @default.
• W3099532404 creator A5015361059 @default.
• W3099532404 creator A5023243807 @default.
• W3099532404 creator A5023482162 @default.
• W3099532404 creator A5024697702 @default.
• W3099532404 creator A5025949000 @default.
• W3099532404 creator A5028184588 @default.
• W3099532404 creator A5040060343 @default.
• W3099532404 creator A5059417834 @default.
• W3099532404 creator A5061450710 @default.
• W3099532404 creator A5086063529 @default.
• W3099532404 creator A5088914285 @default.
• W3099532404 creator A5090500677 @default.
• W3099532404 creator A5090552511 @default.
• W3099532404 date "2020-12-03" @default.
• W3099532404 modified "2023-09-29" @default.
• W3099532404 title "A Pilot Randomized, Controlled, Double‐Blind Trial of Bumetanide to Treat Neonatal Seizures" @default.
• W3099532404 cites W1824596981 @default.
• W3099532404 cites W1923103082 @default.
• W3099532404 cites W1963166481 @default.
• W3099532404 cites W1965968130 @default.
• W3099532404 cites W1973603186 @default.
• W3099532404 cites W1974169328 @default.
• W3099532404 cites W1976784903 @default.
• W3099532404 cites W1978131010 @default.
• W3099532404 cites W1987490682 @default.
• W3099532404 cites W1989221003 @default.
• W3099532404 cites W2005024148 @default.
• W3099532404 cites W2031616555 @default.
• W3099532404 cites W2033366759 @default.
• W3099532404 cites W2034053171 @default.
• W3099532404 cites W2034224142 @default.
• W3099532404 cites W2042553471 @default.
• W3099532404 cites W2054156009 @default.
• W3099532404 cites W2056191555 @default.
• W3099532404 cites W2056958360 @default.
• W3099532404 cites W2077046662 @default.
• W3099532404 cites W2093495611 @default.
• W3099532404 cites W2105645010 @default.
• W3099532404 cites W2113182013 @default.
• W3099532404 cites W2118687598 @default.
• W3099532404 cites W2129934770 @default.
• W3099532404 cites W2135114611 @default.
• W3099532404 cites W2142300947 @default.
• W3099532404 cites W2143807595 @default.
• W3099532404 cites W2144679528 @default.
• W3099532404 cites W2153507803 @default.
• W3099532404 cites W2219526248 @default.
• W3099532404 cites W2291424342 @default.
• W3099532404 cites W2322833765 @default.
• W3099532404 cites W2329510298 @default.
• W3099532404 cites W2338386685 @default.
• W3099532404 cites W2520685154 @default.
• W3099532404 cites W2550044866 @default.
• W3099532404 cites W2587168943 @default.
• W3099532404 cites W2606881087 @default.
• W3099532404 cites W2789449417 @default.
• W3099532404 cites W2894859763 @default.
• W3099532404 cites W2906024028 @default.
• W3099532404 cites W2986661871 @default.
• W3099532404 cites W3021808607 @default.
• W3099532404 cites W33261368 @default.
• W3099532404 doi "https://doi.org/10.1002/ana.25959" @default.
• W3099532404 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8122513" @default.
• W3099532404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33201535" @default.
• W3099532404 hasPublicationYear "2020" @default.
• W3099532404 type Work @default.
• W3099532404 sameAs 3099532404 @default.
• W3099532404 citedByCount "47" @default.
• W3099532404 countsByYear W30995324042021 @default.
• W3099532404 countsByYear W30995324042022 @default.
• W3099532404 countsByYear W30995324042023 @default.
• W3099532404 crossrefType "journal-article" @default.
• W3099532404 hasAuthorship W3099532404A5014884565 @default.
• W3099532404 hasAuthorship W3099532404A5015361059 @default.
• W3099532404 hasAuthorship W3099532404A5023243807 @default.
• W3099532404 hasAuthorship W3099532404A5023482162 @default.
• W3099532404 hasAuthorship W3099532404A5024697702 @default.
• W3099532404 hasAuthorship W3099532404A5025949000 @default.
• W3099532404 hasAuthorship W3099532404A5028184588 @default.
• W3099532404 hasAuthorship W3099532404A5040060343 @default.
• W3099532404 hasAuthorship W3099532404A5059417834 @default.
• W3099532404 hasAuthorship W3099532404A5061450710 @default.
• W3099532404 hasAuthorship W3099532404A5086063529 @default.
• W3099532404 hasAuthorship W3099532404A5088914285 @default.
• W3099532404 hasAuthorship W3099532404A5090500677 @default.
• W3099532404 hasAuthorship W3099532404A5090552511 @default.
• W3099532404 hasBestOaLocation W30995324042 @default.
• W3099532404 hasConcept C118552586 @default.
• W3099532404 hasConcept C126322002 @default.
• W3099532404 hasConcept C142724271 @default.
• W3099532404 hasConcept C168563851 @default.
• W3099532404 hasConcept C178790620 @default.
• W3099532404 hasConcept C185592680 @default.
• W3099532404 hasConcept C187212893 @default.
• W3099532404 hasConcept C188053792 @default.

• next